- Company announces official approval for its common shares to be listed, traded on NYSE American
- Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader
- Companies that list on NYSE American can leverage a wide range of advantages
In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading on or about August 5, 2021, under the symbol CYBN.
“We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” said Cybin CEO Doug Drysdale. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.”
Drysdale noted that the company expected that expanded access to investors would further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions (https://ibn.fm/TssUu).
Designed for growing companies, the NYSE American exchange draws on its heritage as the American Stock Exchange and offers investors greater choice in how they trade (https://ibn.fm/wOUM7). The exchange is a competitively priced venue that blends unique features derived from the NYSE, such as electronic designated market makers (e-DMMs) with quoting obligations for each NYSE American-listed company, with NYSE Arca’s fully electronic price/time priority execution model. Companies that list on the NYSE American can leverage a wide range of advantages, including access to capital, improved branding and visibility, accountability, and increased liquidity.
Cybin also noted that, in addition to listing and trading on the NYSE American in U.S. dollars, Cybin’s common shares will continue to be listed and trade in Canada on the NEO Exchange in Canadian dollars, also under the symbol CYBN.
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.